Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer
Background and Objectives
Lurbinectedin is an inhibitor of RNA polymerase II currently under clinical development for intravenous administration as a single agent and in combination with other anti-tumor agents for the treatment of several tumor types. The objective of this work was to develop a population-pharmacokinetic model in this patient setting and to elucidate the main predictors to guide the late stages of development.
Data from 443 patients with solid and hematologic malignancies treated in six phase I and three phase II trials with lurbinectedin as a single agent or combined with other agents were included in the analysis. The potential influence of demographic, co-treatment, and laboratory characteristics on lurbinectedin pharmacokinetics was evaluated.
The final population-pharmacokinetic model was an open three-compartment model with linear distribution and linear elimination from the central compartment. Population estimates for total plasma clearance, and apparent volume at steady state were 11.2 L/h and 438 L, respectively. Inter-individual variability was moderate for all parameters, ranging from 20.9 to 51.2%. High α-1-acid glycoprotein and C-reactive protein, and low albumin reduced clearance by 28, 20, and 20%, respectively. Co-administration of cytochrome P450 3A inhibitors reduced clearance by 30%. Combinations with other anti-tumor agents did not modify the pharmacokinetics of lurbinectedin significantly.
The population-pharmacokinetic model indicated neither a dose nor time dependency, and no clinically meaningful pharmacokinetic differences were found when co-administered with other anticancer agents. A chronic inflammation pattern characterized by decreased albumin and increased C-reactive protein and α-1-acid glycoprotein levels led to high lurbinectedin exposure. Co-administration of cytochrome P450 3A inhibitors increased lurbinectedin exposure.
The authors thank the patients, their families, and the clinical research teams for their time and trust, and for making these clinical trials and associated research possible.
Compliance with Ethical Standards
All analyses were funded by PharmaMar, S.A.
Conflict of interest
Carlos Fernandez-Teruel, Ignacio Gonzalez, Rubin Lubomirov, Arturo Soto, and Salvador Fudio are employees and shareholders of PharmaMar S.A. Iñaki F. Trocóniz received a consulting honorarium from PharmaMar S.A.
- 6.Paz-Ares L, Forster M, Boni V, Szyldergemajn S, Corral J, Turnbull S, et al. Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors. Investig New Drugs. 2017;35(2):198–206.CrossRefGoogle Scholar
- 7.Sauri T, Awada A, Calvo E, Moreno V, Szyldergemajn S, Elez E, et al. Lurbinectedin (PM01183) administered once (C1) every 3 weeks (q3w) in combination with capecitabine (XEL) in patients (pts) with metastatic breast (MBC), colorectal (CRC) or pancreatic (PaC) cancer. Eur J Cancer. 2016;27(Suppl. 6):392P.Google Scholar
- 8.European Medicines Agency. Yondelis® (trabectedin): summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000773/WC500045832.pdf. Accessed 22 Jun 2018.
- 9.US Food and Drug Administration. Yondelis® (trabctedin): prescription information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207953s000lbl.pdf. Accessed 22 Jun 2018.
- 10.PharmaMar. Clinical trial of lurbinectedin (PM01183)/doxorubicin (DOX) versus cyclophosphamide (CTX), doxorubicin (DOX) and vincristine (VCR) (CAV) or topotecan as treatment in patients with small-cell lung cancer. 2019. https://ClinicalTrials.gov/show/NCT02566993. Accessed Mar 2018.
- 11.PharmaMar. Clinical trial of lurbinectedin (PM01183) in selected advanced solid tumors. 2019. https://ClinicalTrials.gov/show/NCT02454972. Accessed 23 Jul 2018.
- 12.PharmaMar. Clinical trial of lurbinectedin (PM01183) in platinum resistant ovarian cancer patients. 2018. https://ClinicalTrials.gov/show/NCT02421588. Accessed 23 Jul 2018.
- 16.Jonsson EN, Karlsson MO. Xpose: an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. J Biomech. 1998;58(1):51–64.Google Scholar
- 20.Jimeno A, Sharma MR, Szyldergemajn S, Gore L, Geary D, Diamond JR, et al. Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule. Investig New Drugs. 2017;35(4):471–7.CrossRefGoogle Scholar
- 23.Fernandez-Teruel C, Del Campo JM, Berton-Rigaud D, Ray-Coquard I, Alexandre J, Provansal M, et al. Lurbinectedin (PM01183) efficacy in platinum-resistant/refractory ovarian cancer (PRROC) patients correlates with drug exposure using pharmacokinetic/pharmacodynamic (PK/PD) modelling. In: 19th international meeting of the European Society of Gynaecological (ESGO), Nice, France, 24–27 October. Int J Gynecol Cancer. 2015;25(2_suppl);433.Google Scholar
- 29.PharmaMar. Clinical study of PM01183 in patients with acute leukemia or relapsed/refractory myelodysplastic syndrome. https://ClinicalTrials.gov/show/NCT01314599. Accessed 2 Mar 2018.
- 30.Patel H, Egorin MJ, Remick SC, Mulkerin D, Takimoto CHM, Doroshow JH, et al. Comparison of Child-Pugh (CP) criteria and NCI Organ Dysfunction Working Ggroup (NCI-ODWG) criteria for hepatic dysfunction (HD): implications for chemotherapy dosing. Am J Clin Oncol. 2004;22(14_Suppl):6051.CrossRefGoogle Scholar
- 31.Benton CB, Pavon JRD, Maiti A, Daver NG, Ravandi F, Jain N, Alvarado Y, Jabbour E, Pierce S, Kwari M, Santos MA, Martinez S, Siguero M, Tefferi A, Cortes JE, Kantarjian HM, Pardanani AD, Garcia-Manero G. Phase I study of lurbinectedin (PM11083) in patients with advanced AML and MDS. J Clin Oncol. 2017;35(15_suppl):e18521. https://doi.org/10.1200/JCO.2017.35.15_suppl.e18521.CrossRefGoogle Scholar